{"entity":{"id":"volitionrx","kind":"company","name":"VolitionRx","aka":[],"tldr":"VolitionRx develops low-cost blood tests that measure nucleosomes, the packaging units of DNA released by dying cells, to detect and monitor cancer and sepsis.","summary":"VolitionRx Limited, listed on NYSE American as VNRX, is an epigenetics diagnostics company with a 20,000 square foot laboratory and manufacturing site in Gembloux (Isnes), Belgium and executive offices in the United States. Its Nucleosomics platform quantifies circulating nucleosomes and their epigenetic modifications in a routine blood sample using immunoassays that run on standard clinical analysers. Products include Nu.Q NETs, a CE-marked assay for NETosis in sepsis being commercialised with Sysmex; Nu.Q Vet Cancer Test, a canine screening test reported to detect 76 percent of systemic cancers at 97 percent specificity; Nu.Q Discover research assays; and the Nu.Q Cancer pipeline, including a Nu.Q Lung Cancer test being prepared for reimbursement submission with Hospices Civils de Lyon.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://volition.com/"},{"label":"Investor relations","url":"https://ir.volition.com/"},{"label":"Q2 2026 results (Aug 2026)","url":"https://volition.com/volitionrx-limited-announces-second-quarter-2026-financial-results-and-business-update"}],"tags":[],"related":[],"cancers":["nsclc"],"sections":["diagnostics","early-detection"],"technologies":["liquid-biopsy","mced"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["The Q2 2026 release dateline is Henderson, Nevada, not Austin, Texas; the website describes Gembloux, Belgium as the primary operating site. Human cancer tests remain in development; only the veterinary and NETs assays are commercial."],"hq":"Henderson, NV","country":"US","companyType":"diagnostics","website":"https://volition.com/","ticker":"VNRX","stage":"public","investors":[],"funding":[]},"route":"/companies/volitionrx/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"section":[{"id":"diagnostics","kind":"section","name":"Diagnostics & Biomarkers","route":"/fronts/diagnostics/"},{"id":"early-detection","kind":"section","name":"Early Detection & Screening","route":"/fronts/early-detection/"}],"technology":[{"id":"liquid-biopsy","kind":"technology","name":"Liquid biopsy (ctDNA)","route":"/technologies/liquid-biopsy/"},{"id":"mced","kind":"technology","name":"Multi-cancer early detection (MCED)","route":"/technologies/mced/"}]}}